AstraZeneca : Granted US FDA Priority Review for Anti-Stroke Drug Brilinta

By Sabela Ojea

AstraZeneca PLC said Thursday that the U.S. Food and Drug Administration has accepted a supplemental new drug application and granted a priority review for its Brilinta drug for the treatment of strokes in high-risk patients.

The biopharmaceutical company said the Prescription Drug User Fee Act date for the supplemental application is scheduled for the fourth quarter of 2020.

"Patients who have had an acute ischaemic stroke or transient ischemic attack are at high risk of experiencing a subsequent stroke, which may be disabling or fatal," said Mene Pangalos, executive vice president at AstraZeneca's biopharmaceuticals research-and-development team.

Write to Sabela Ojea at [e-mail]; @sabelaojeaguix